"FDA Panel Rejects MDMA Therapy for PTSD"

An FDA advisory committee voted against approving MDMA therapy for PTSD, citing concerns over the integrity of clinical trial data and ethical issues. This decision, which the FDA is likely to follow, could delay the legalization of MDMA and other psychedelics for medical use. The committee's vote reflects skepticism about the current evidence supporting MDMA's efficacy and safety, despite promising trial results. The FDA's final decision is expected by August 11.